IRIS
Conforti, Fabio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.019
AS - Asia 571
EU - Europa 254
SA - Sud America 125
Continente sconosciuto - Info sul continente non disponibili 98
AF - Africa 22
Totale 2.089
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 963
SG - Singapore 246
IT - Italia 153
CN - Cina 142
BR - Brasile 95
VN - Vietnam 64
HK - Hong Kong 28
CA - Canada 24
FR - Francia 22
IN - India 21
MX - Messico 16
GB - Regno Unito 15
ID - Indonesia 11
BD - Bangladesh 9
DE - Germania 9
FI - Finlandia 9
PH - Filippine 9
AR - Argentina 8
RU - Federazione Russa 8
IE - Irlanda 7
IQ - Iraq 7
JM - Giamaica 6
MA - Marocco 6
SA - Arabia Saudita 6
EG - Egitto 5
ES - Italia 5
JP - Giappone 5
CL - Cile 4
EC - Ecuador 4
MY - Malesia 4
NG - Nigeria 4
PE - Perù 4
KH - Cambogia 3
NI - Nicaragua 3
PK - Pakistan 3
PY - Paraguay 3
QA - Qatar 3
RS - Serbia 3
TR - Turchia 3
AL - Albania 2
AT - Austria 2
BY - Bielorussia 2
CH - Svizzera 2
CO - Colombia 2
GT - Guatemala 2
HN - Honduras 2
NL - Olanda 2
PL - Polonia 2
PR - Porto Rico 2
UA - Ucraina 2
UY - Uruguay 2
VE - Venezuela 2
ZA - Sudafrica 2
AO - Angola 1
BG - Bulgaria 1
BO - Bolivia 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DK - Danimarca 1
DZ - Algeria 1
GM - Gambi 1
GR - Grecia 1
HR - Croazia 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
NP - Nepal 1
OM - Oman 1
RO - Romania 1
SE - Svezia 1
SI - Slovenia 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
Totale 1.991
Salva come PNG Salva come JPEG
Città #
Council Bluffs 98
Singapore 73
Santa Clara 68
Milan 57
San Jose 57
Ashburn 54
New York 34
Beijing 33
Phoenix 33
Hong Kong 28
Ho Chi Minh City 26
Los Angeles 25
Buffalo 20
Rome 19
Dallas 18
Shanghai 18
The Dalles 18
Chandler 17
Hanoi 13
Naples 13
Brooklyn 12
São Paulo 12
Helsinki 9
Princeton 9
Wilmington 9
Charlotte 7
Miami 7
Dublin 6
Las Vegas 6
Paris 6
Philadelphia 6
Baghdad 5
Hillsboro 5
Mexico City 5
San Diego 5
Benin City 4
Casablanca 4
Houston 4
Kingston 4
Lancaster 4
Lawrence 4
London 4
Louisville 4
Montreal 4
Nanjing 4
Rio de Janeiro 4
Seattle 4
Staten Island 4
Turin 4
Atlanta 3
Belgrade 3
Belo Horizonte 3
Boston 3
Cairo 3
Da Nang 3
Dammam 3
Doha 3
Huntington Beach 3
Lima 3
Managua 3
Padua 3
Phnom Penh 3
Queens 3
San Francisco 3
Santiago 3
Toronto 3
Acapulco de Juárez 2
Arlington 2
Assago 2
Baltimore 2
Bari 2
Bologna 2
Bossier City 2
Cary 2
Catania 2
Caxias do Sul 2
Charleston 2
Chicago 2
Chula Vista 2
City of London 2
Cleveland 2
Columbus 2
Coral Springs 2
Cuauhtémoc 2
Curitiba 2
Davenport 2
Denver 2
Detroit 2
Elk Grove 2
Fayetteville 2
Florence 2
Freehold 2
Fremont 2
Fresno 2
Gilbert 2
Guaratuba 2
Guarulhos 2
Guatemala City 2
Hangzhou 2
Jakarta 2
Totale 1.006
Salva come PNG Salva come JPEG
Nome #
The Rare Entity of Basaloid Thymic Carcinoma: A Multicentric Retrospective Analysis from the Italian Collaborative Group for ThYmic MalignanciEs (TYME) 100
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 92
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial 81
Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy 66
Clinical management of patients with thymic epithelial tumors: the recommendations endorsed by the Italian Association of Medical Oncology (AIOM) 63
SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis 59
Macrophages and bone metastasis 56
Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma 56
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 53
Muscle and Muscle-like Autoantigen Expression in Myasthenia Gravis Thymus: Possible Molecular Hint for Autosensitization 42
Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group 41
Bridging Knowledge Gaps in Small Cell Lung Cancer: Data, Challenges and Priorities 41
Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study 39
Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy 38
Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers 36
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. 33
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. 32
Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors 29
Aprepitant use during chemotherapy and association with survival in women with early breast cancer 27
Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature 26
Comparison of filgrastim and pegfilgrastim prophylaxis in sarcoma patients receiving highly myelosuppressive chemotherapy 25
A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy 25
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis 25
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy 23
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis 23
Boosting anticancer immunotherapy through androgen receptor blockade 22
“Heterogeneity of treatment effect on patients’ long-term outcome according to pathological response type in neoadjuvant RCTs for breast cancer.” 22
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy 21
Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study 21
Sex hormones, the anticancer immune response, and therapeutic opportunities 21
Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E 20
Biological and clinical features of early triple-negative invasive lobular carcinomas of the breast 20
Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19 19
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations 18
Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center 18
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity 18
Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment 18
Metaplastic breast cancer: Prognostic and therapeutic considerations 17
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy 17
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion 17
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma 17
Association of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials A Systematic Review and Meta-analysis 17
Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AML 17
Successful treatment with avapritinib in patient with mucosal metastatic melanoma 17
The rare entity of gastrointestinal leiomyosarcomas: An Italian multicenter retrospective study in high‐volume referral centers 16
Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer Critical Analysis of Strengths, Weaknesses, and Misinterpretations 16
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis 15
Differential activity of avapritinib in patients with metastases from mucosal melanoma and thymic carcinoma harbouring KIT exon 17 mutations: Initial experience from a Compassionate Use Program in Italy 15
Endocrine-responsive lobular carcinoma of the breast: features associated with risk of late distant recurrence 15
Different Response to Immunotherapy According to Melanoma Histologic Subtype 15
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors ceritinib 14
Under-representation of women in Randomized Clinical Trials testing anticancer immunotherapy may undermine female patients care. A call to action 14
High-dose continuous-infusion ifosfamide in advanced thymic epithelial Tumors: A TYME network study 13
Sex and cancer immunotherapy: Current understanding and challenges 13
Xpo1 Inhibition: A Promising Therapeutic Strategy in Thymic Epithelial Tumors 13
EPIDERMAL GROWTH FACTORS TYROSINE-KINASE INHIBITORS (EGFR-TKI) EFFICACY IN NSCLC PATIENTS WITH HIGH POLYSOMY OF CHROMOSOME 7 AND EGFR/KRAS WILD TYPE TUMORS 13
Sex as a predictor of response to cancer immunotherapy Reply 13
Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome 13
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials 13
Ethnicity-based differences in breast cancer features and responsiveness to CDK4/6 inhibitors combined with endocrine therapy 13
Sex-related differences in patients with coronavirus disease 2019: results of the Cardio-COVID-Italy multicentre study 12
Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator? 12
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma 12
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis 12
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis 12
EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung 12
EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials 12
Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome 11
Original Research Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy 11
Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the Microbiome 11
Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex Factors 11
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors 11
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer 11
Sex-based differences of the intratumoral immune-infiltrate 11
Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice 11
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials 11
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial 11
Extended Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients 11
The effect of patient sex on the efficacy and safety of anticancer immunotherapy 11
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review 11
Immune-checkpoint inhibitors in anal squamous cell carcinoma: a systematic review and meta-analysis 11
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis 10
Sex-based dimorphism in the SARS-CoV2 virulence 10
Thymic epithelial tumors: From biology to treatment 10
Tailoring the optimal duration of the extended adjuvant endocrine therapy in patients with early-stage breast cancer. A systematic review and meta-analysis of randomized clinical trials 10
Targeting ALK in patients with advanced Non Small Cell Lung Cancer: Biology, diagnostic and therapeutic options 10
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis 9
Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors 9
Molecular Pathways: Anticancer Activity by Inhibition of Nucleocytoplasmic Shuttling 9
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review 9
Genetic Alterations of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis 9
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials 8
Gender-Based Differences in the Efficacy of Anti-EGFR/BRAF/MEK Targeted Therapy in Patients with BRAF-Mutated Metastatic Colorectal Cancer 8
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors 8
Erlotinib Efficacy in NSCLC Patients with High Polysomy of Chromosome 7 and EGFR/KRas Wild-Type Tumors 7
Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature 7
Molecular features and clinical outcome of lung malignancies in very young people 6
Totale 2.089
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.593
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.593
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202220 0 0 0 2 0 0 0 4 3 2 9 0
2022/202358 9 0 4 7 3 5 0 5 12 6 6 1
2023/202446 0 6 7 1 0 9 6 4 0 1 5 7
2024/2025124 5 2 1 1 0 11 11 12 15 29 14 23
2025/20261.143 42 17 17 53 21 23 96 315 144 101 65 249
2026/2027678 124 175 358 21 0 0 0 0 0 0 0 0
Totale 2.089